Skip to main content

Table 1 List of BCR-ABL1 KD mutations poorly sensitive to imatinib, dasatinib, nilotinib, bosutinib, and ponatinib based on the integration of published studies (2001–2018) reporting the mutation status of TKI-resistant patients and experimental data

From: Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper

Mutations poorly sensitive to imatinib

M237V, I242T, M244 V, K247R, L248V, G250E, G250R, Q252R, Q252H, Y253F, Y253H, E255K, E255V, E258D, W261L, L273M, E275K, E275Q, D276G, T277A, E279K, V280A, V289I, V289I, V289A, E292Q, E292V, I293V, L298V, F311L, F311I, T315I, F317L, F317V, F317I, F317C, Y320C, L324Q, Y342H, M343T, A344V, A350V, M351T, E355D, E355G, E355A, F359V, F359I, F359C, F359L, D363Y, L364I, A365V, A366G, L370P, V371A, E373K, V379I, A380T, F382L, L384M, L387F, L387V, M388L, H396R, H396P, H396A, A397P, S417F, S417Y, I418S, I418V, A433T, S438C, E450K, E450G, E450A, E450V, E453G, E453A, E453K, E453V, E453Q, E459K, E459V, E459G, E459Q, M472I, P480L, F486S

Mutations poorly sensitive to dasatinib

V299L, T315I, T315A, F317L, F317V, F317I, F317C

Mutations poorly sensitive to nilotinib

Y253H, E255K, E255V, T315I, F359V, F359I, F359C

Mutations poorly sensitive to bosutiniba

E255V, E255K, V299L, T315I

Mutations poorly sensitive to ponatinib

T315M, T315L

  1. aIn contrast to the other second-generation TKIs, there is still limited data available on mutations associated with clinical resistance to bosutinib in vivo. In vitro data suggest that the E255K and, to a lesser extent, the E255V might be poorly sensitive to bosutinib [15]
  2. TKI tyrosine kinase inhibitor
  3. The most frequent imatinib-resistant mutations are highlighted in boldface
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us